DR. THOMAS K BARLIS DPM
Prescription History 1376540021
Podiatrist in Astoria, NY

NPI Status: Active since July 07, 2005

Contact Information

2747 CRESCENT ST
SUITE 204
ASTORIA, NY
ZIP 11102
Phone: (718) 956-0700
Fax: (718) 956-4582

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. THOMAS K BARLIS DPM, an active Podiatrist specialist practicing in Astoria, NY. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 133 documented patient claims. Among these therapy options, the most frequently utilized medication is Ammonium Lactate, which accounts for 38 claims alone.

Medication Index


Ammonium Lactate

Generic Formulation: Ammonium LactateSpecialty: Podiatry
Provider Metrics Summary
Total Claims 38
30-Day Fills 38.0
Days Supply 1,105
NY State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills85.9
Peer Average Days Supply2,525
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,062.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.96

State Avg Cost Per Claim

$28.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)

Therapeutic Applications

This medication is used to treat dry, scaly skin conditions (such as xerosis, ichthyosis vulgaris) and can also help relieve itching from these conditions. This medication works by increasing the moisture in the skin.

Clotrimazole

Generic Formulation: ClotrimazoleSpecialty: Podiatry
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 395
NY State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills55.3
Peer Average Days Supply1,534
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $305.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.84

State Avg Cost Per Claim

$37.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Therapeutic Applications

Clotrimazole is used to treat skin infections such as athlete's foot, jock itch, ringworm, and other fungal skin infections (candidiasis). This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Clotrimazole is an azole antifungal that works by preventing the growth of fungus.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Podiatry
Provider Metrics Summary
Total Claims 31
30-Day Fills 32.0
Days Supply 848
NY State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply825
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,411.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.53

State Avg Cost Per Claim

$38.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Podiatry
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 620
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills66.8
Peer Average Days Supply1,938
Conservative Utilization

This provider writes prescriptions for this formulation 39.6% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $125.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.34

State Avg Cost Per Claim

$5.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Silver Sulfadiazine

Generic Formulation: Silver SulfadiazineSpecialty: Podiatry
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 434
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills35.0
Peer Average Days Supply655
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $168.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.04

State Avg Cost Per Claim

$19.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial used topically in burn therapy.

Therapeutic Applications

This medication is used with other treatments to help prevent and treat wound infections in patients with serious burns. Silver sulfadiazine works by stopping the growth of bacteria that may infect an open wound. This helps to decrease the risk of the bacteria spreading to surrounding skin, or to the blood where it can cause a serious blood infection (sepsis). Silver sulfadiazine belongs to a class of drugs known as sulfa antibiotics. Silver sulfadiazine must not be used on premature babies or on newborns during the first 2 months of life because of the risk of serious side effects.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. THOMAS K BARLIS DPM provides transparency into local medical care patterns within Astoria, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Podiatrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.